These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 11835371)

  • 1. Dopaminergic modulation of cortical function in patients with Parkinson's disease.
    Mattay VS; Tessitore A; Callicott JH; Bertolino A; Goldberg TE; Chase TN; Hyde TM; Weinberger DR
    Ann Neurol; 2002 Feb; 51(2):156-64. PubMed ID: 11835371
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of levodopa on corticostriatal circuits supporting working memory in Parkinson's disease.
    Simioni AC; Dagher A; Fellows LK
    Cortex; 2017 Aug; 93():193-205. PubMed ID: 28675834
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dopamine depletion impairs gait automaticity by altering cortico-striatal and cerebellar processing in Parkinson's disease.
    Gilat M; Bell PT; Ehgoetz Martens KA; Georgiades MJ; Hall JM; Walton CC; Lewis SJG; Shine JM
    Neuroimage; 2017 May; 152():207-220. PubMed ID: 28263926
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dopaminergic modulation of striato-frontal connectivity during motor timing in Parkinson's disease.
    Jahanshahi M; Jones CR; Zijlmans J; Katzenschlager R; Lee L; Quinn N; Frith CD; Lees AJ
    Brain; 2010 Mar; 133(Pt 3):727-45. PubMed ID: 20305278
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dopaminergic modulation of motor network dynamics in Parkinson's disease.
    Michely J; Volz LJ; Barbe MT; Hoffstaedter F; Viswanathan S; Timmermann L; Eickhoff SB; Fink GR; Grefkes C
    Brain; 2015 Mar; 138(Pt 3):664-78. PubMed ID: 25567321
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cortical activity in Parkinson's disease during executive processing depends on striatal involvement.
    Monchi O; Petrides M; Mejia-Constain B; Strafella AP
    Brain; 2007 Jan; 130(Pt 1):233-44. PubMed ID: 17121746
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dopaminergic modulation of cognitive interference after pharmacological washout in Parkinson's disease.
    Fera F; Nicoletti G; Cerasa A; Romeo N; Gallo O; Gioia MC; Arabia G; Pugliese P; Zappia M; Quattrone A
    Brain Res Bull; 2007 Sep; 74(1-3):75-83. PubMed ID: 17683792
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Schizophrenia and Parkinson's disease lead to equal motor-related changes in cortical and subcortical brain activation: an fMRI fingertapping study.
    Müller JL; Deuticke C; Putzhammer A; Röder CH; Hajak G; Winkler J
    Psychiatry Clin Neurosci; 2003 Dec; 57(6):562-8. PubMed ID: 14629703
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Common Function of Basal Ganglia-Cortical Circuits Subserving Speed in Both Motor and Cognitive Domains.
    Hanakawa T; Goldfine AM; Hallett M
    eNeuro; 2017; 4(6):. PubMed ID: 29379873
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mesocortical dopaminergic function and human cognition.
    Weinberger DR; Berman KF; Chase TN
    Ann N Y Acad Sci; 1988; 537():330-8. PubMed ID: 2974264
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dopaminergic modulation of motor network compensatory mechanisms in Parkinson's disease.
    Jastrzębowska MA; Marquis R; Melie-García L; Lutti A; Kherif F; Herzog MH; Draganski B
    Hum Brain Mapp; 2019 Oct; 40(15):4397-4416. PubMed ID: 31291039
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dopamine modulates the response of the human amygdala: a study in Parkinson's disease.
    Tessitore A; Hariri AR; Fera F; Smith WG; Chase TN; Hyde TM; Weinberger DR; Mattay VS
    J Neurosci; 2002 Oct; 22(20):9099-103. PubMed ID: 12388617
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dopaminergic modulation of high-level cognition in Parkinson's disease: the role of the prefrontal cortex revealed by PET.
    Cools R; Stefanova E; Barker RA; Robbins TW; Owen AM
    Brain; 2002 Mar; 125(Pt 3):584-94. PubMed ID: 11872615
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dopaminergic medication normalizes aberrant cognitive control circuit signalling in Parkinson's disease.
    Cai W; Young CB; Yuan R; Lee B; Ryman S; Kim J; Yang L; Henderson VW; Poston KL; Menon V
    Brain; 2022 Nov; 145(11):4042-4055. PubMed ID: 35357463
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Levodopa influences striatal activity but does not affect cortical hyper-activity in Parkinson's disease.
    Martinu K; Degroot C; Madjar C; Strafella AP; Monchi O
    Eur J Neurosci; 2012 Feb; 35(4):572-83. PubMed ID: 22304628
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Levodopa reinstates connectivity from prefrontal to premotor cortex during externally paced movement in Parkinson's disease.
    Herz DM; Siebner HR; Hulme OJ; Florin E; Christensen MS; Timmermann L
    Neuroimage; 2014 Apr; 90():15-23. PubMed ID: 24269570
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Functional mapping of dopaminergic transmission].
    Sawamoto N
    Rinsho Shinkeigaku; 2007 Nov; 47(11):832-4. PubMed ID: 18210810
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Abnormal basal ganglia outflow in Parkinson's disease identified with PET. Implications for higher cortical functions.
    Owen AM; Doyon J; Dagher A; Sadikot A; Evans AC
    Brain; 1998 May; 121 ( Pt 5)():949-65. PubMed ID: 9619196
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduced topological efficiency in cortical-basal Ganglia motor network of Parkinson's disease: a resting state fMRI study.
    Wei L; Zhang J; Long Z; Wu GR; Hu X; Zhang Y; Wang J
    PLoS One; 2014; 9(10):e108124. PubMed ID: 25279557
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Functional segregation of basal ganglia pathways in Parkinson's disease.
    Neumann WJ; Schroll H; de Almeida Marcelino AL; Horn A; Ewert S; Irmen F; Krause P; Schneider GH; Hamker F; Kühn AA
    Brain; 2018 Sep; 141(9):2655-2669. PubMed ID: 30084974
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.